Similarly, in glioblastoma and ovarian cancer, combination therapy of anti-CXCR4 and anti-PD-1 is also demonstrated to decrease populations of immunosuppressive tumor-infiltrating MDSCs, improve CD4+/CD8+ ratios, and confer a significant survival benefit compared to control and monotherapy arms (79, 114). The gene discussed is CXCR4; the disease is neoplasm.